Longeveron Inc. - Class A Common stock (NQ:LGVN)

1.670 -0.080 (-4.57%)

Delayed Quote Updated: 4:00 PM EDT, Oct 30, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Longeveron Inc. - Class A Common stock

< Previous 1 2

...

5 6 7 8 9 10 11 12 13

...

16 17 Next >

Longeveron (NASDAQ: LGVN) Reports 100% 5-Year Survival In Trial For Rare Pediatric Disease HLHS (Compared To 80% Survival In Historical Trials) To Market ↗

September 11, 2023

Advancements in healthcare and medicine have helped contribute to the reduction in child mortality rates, plummeting from 185 per 1,000 births a century ago to just 7 per 1,000 births in 2020. However,...

Via Benzinga

Longeveron Inc. (NASDAQ: LGVN) Is ‘One to Watch’

September 08, 2023

Via Investor Brand Network

BioMedNewsBreaks — Longeveron Inc. (NASDAQ: LGVN; LGVNR) Announces ELPIS 1 Trial Data Accepted for AHA Presentation, IBN Partnership

September 07, 2023

Via Investor Brand Network

Upcoming Phase 2 Data Expected For Longeveron’s (NASDAQ: LGVN) Drug For the $4+ Billion Alzheimer’s Sector – What To Look For

September 07, 2023

--News Direct--

Via News Direct

Earnings Preview: Longeveron ↗

August 10, 2023

Via Benzinga

LGVN Stock Earnings: Longeveron Misses EPS, Revenue Estimates ↗

May 12, 2023

LGVN stock earnings show Longeveron reporting a wider loss than analysts expected and missing revenue estimates.

Via InvestorPlace

Recap: Longeveron Q1 Earnings ↗

May 12, 2023

Via Benzinga

Preview: Longeveron's Earnings ↗

May 11, 2023

Via Benzinga

Upcoming Phase 2 Data Expected For Longeveron’s (NASDAQ: LGVN) Drug For the $4+ Billion Alzheimer’s Sector – What To Look For

September 07, 2023

By David Willey, Benzinga

Via TheNewswire.com

Upcoming Phase 2 Data Expected For Longeveron's (NASDAQ: LGVN) Drug For the $4+ Billion Alzheimer's Sector – What To Look For ↗

September 06, 2023

Longeveron (NASDAQ: LGVN), a clinical-stage biopharma developing potential treatments for age-related and life-threatening diseases, is expecting data from its phase 2a trial for its Lomecel-B™...

Via Benzinga

BioMedNewsBreaks – Longeveron Inc. (NASDAQ: LGVN) to Present at Upcoming H.C. Wainwright Global Investment Conference

September 05, 2023

Via Investor Brand Network

US Stocks Rise; Initial Jobless Claims Edge Lower ↗

August 31, 2023

U.S. stocks traded higher this morning, following the release of economic reports. Following the market opening Thursday, the Dow traded up 0.26% to 34,982.42 while the NASDAQ rose 0.48% to 14,086.54....

Via Benzinga

Topics Stocks

Why Lands' End Are Trading Lower By 22%? Here Are Other Stocks Moving In Thursday's Mid-Day Session ↗

August 31, 2023

Gainers Acer Therapeutics Inc. (NASDAQ: ACER) shares jumped 145% to $1.4850 after Zevra Therapeutics announced it will acquire the company. The transaction will have a total potential value for Acer...

Via Benzinga

12 Health Care Stocks Moving In Thursday's Pre-Market Session ↗

August 31, 2023

Via Benzinga

BioMedNewsBreaks — Longeveron Inc. (NASDAQ: LGVN; LGVNR) Announces Participation at Upcoming National Investment Banking Association Conference

August 30, 2023

Via Investor Brand Network

As America Grapples With A Deadly Opioid Epidemic, BioRestorative Therapies Is Looking To Treat Chronic Pain Without The Need For Class-A Drugs ↗

August 29, 2023

Chronic back pain is a significant issue in the United States, affecting millions of individuals annually. According to experts, up to 80% of the population will experience back pain at some point.

Via Benzinga

Earnings Scheduled For August 11, 2023 ↗

August 11, 2023

Companies Reporting Before The Bell • Consolidated Water Co (NASDAQ:CWCO) is estimated to report quarterly earnings at $0.22 per share on revenue of $30.27 million.

Via Benzinga

Longeveron Announces Key Additions To Its Leadership Team and Board As It Gears Up For Phase 2 Trials For Its Lead Drug Candidate For Several Conditions

August 08, 2023

By David Willey, Benzinga

Via TheNewswire.com

Longeveron Announces Key Additions To Its Leadership Team and Board As It Gears Up For Phase 2 Trials For Its Lead Drug Candidate For Several Conditions

August 08, 2023

--News Direct--

Via News Direct

Longeveron – This Biotech Company Is Using The Body's Own Cells To Fight Age-Related Diseases ↗

August 07, 2023

Wa'el Hashad, CEO of Longeveron (NASDAQ: LGVN), was recently interviewed by Benzinga.

Via Benzinga

Longeveron Announces Key Additions To Its Leadership Team And Board As It Gears Up For Phase 2 Trials For Its Lead Drug Candidate For Several Conditions ↗

August 07, 2023

Longeveron, Inc. (NASDAQ: LGVN) is a clinical-stage biopharmaceutical company focused on therapies for age-related and life-threatening diseases.

Via Benzinga

Longeveron – Regenerative Medicine Developer Announces 100% Long Term Survival Rate For Children With HLHS ↗

July 11, 2023

Hypoplastic left heart syndrome, or HLHS, has a historical mortality rate of 20% within five years of diagnosis. The disease affecting children may have a new therapy in Longeveron’s (NASDAQ: LGVN)...

Via Benzinga

12 Health Care Stocks Moving In Friday's Pre-Market Session ↗

July 07, 2023

Via Benzinga

HLHS Is A Rare And Serious Congenital Heart Disease With A 33% Neonatal Death Rate — Could Longeveron’s Lomecel-B Improve Outcomes?

July 07, 2023

HLHS Is A Rare And Serious Congenital Heart Disease With A 33% Neonatal Death Rate — Could Longeveron’s Lomecel-B Improve Outcomes?

Via News Direct

HLHS Is A Rare And Serious Congenital Heart Disease With A 33% Neonatal Death Rate — Could Longeveron’s Lomecel-B Improve Outcomes?

July 07, 2023

By David Willey, Benzinga

Via TheNewswire.com

HLHS Is A Rare And Serious Congenital Heart Disease With A 33% Neonatal Death Rate — Could Longeveron's Lomecel-B Improve Outcomes? ↗

June 28, 2023

Longeveron (NASDAQ: LGVN) announced the results of its phase 1 trial for infants with a rare and serious congenital heart disease (CHD), known as hypoplastic left heart syndrome.

Via Benzinga

Earnings Scheduled For May 12, 2023 ↗

May 12, 2023

Companies Reporting Before The Bell • Honda Motor Co (NYSE:HMC) is expected to report earnings for its fourth quarter.

Via Benzinga

Longeveron's Lomecel-BTM Shows Encouraging Survival Data, Keeps Hypoplastic Left Heart Syndrome Pediatric Patients Heart Transplant-Free ↗

May 09, 2023

Longeveron Inc (NASDAQ: LGVN) announced new long-term follow-up data from its ELPIS I trial of Lomecel-BTM for patients with

Via Benzinga

12 Health Care Stocks Moving In Tuesday's Intraday Session ↗

May 09, 2023

Via Benzinga

Why PRA Group Shares Are Trading Lower By 44%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session ↗

May 09, 2023

Gainers TScan Therapeutics, Inc. (NASDAQ: TCRX) shares gained 118% to $4.68 after the company and Amgen announced collaboration to identify novel targets in Crohn's disease.

Via Benzinga

< Previous 1 2

...

5 6 7 8 9 10 11 12 13

...

16 17 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.